#1 Clinical Trials Search in Europe

Bp1.7881A

BP1.7881A is an innovative drug currently undergoing clinical trials for the treatment of two distinct conditions: atopic dermatitis and eosinophilic esophagitis. This article will provide an overview of the ongoing research, highlighting the potential benefits and safety profile of BP1.7881A in addressing these challenging medical conditions.

Table of Contents

What is BP1.7881A?

BP1.7881A is a new medication currently being studied for the treatment of two different conditions: atopic dermatitis and eosinophilic esophagitis. It is described as a highly potent, selective, orally active dual histamine H1 and H4 receptors antagonist[1]. This means it works by blocking two different types of histamine receptors in the body, which play a role in allergic and inflammatory responses.

Atopic Dermatitis Study

One of the ongoing clinical trials is investigating BP1.7881A for the treatment of moderate to severe atopic dermatitis in adults[1]. Atopic dermatitis, also known as eczema, is a chronic skin condition characterized by itchy, inflamed skin.

The study aims to evaluate:

  • The effectiveness of BP1.7881A in reducing the severity of atopic dermatitis symptoms
  • The safety of the medication
  • How well patients tolerate the treatment

Researchers are particularly interested in measuring changes in the Eczema Area Severity Index (EASI) score, which is a tool used to assess the extent and severity of eczema[1].

Eosinophilic Esophagitis Study

Another clinical trial is investigating BP1.7881A for the treatment of eosinophilic esophagitis (EoE) in adults[2]. EoE is a chronic allergic inflammatory disease of the esophagus, which can cause difficulty swallowing, chest pain, and other digestive symptoms.

This study aims to evaluate:

  • The effect of BP1.7881A on reducing eosinophil (a type of white blood cell) infiltration in the esophagus
  • Improvements in symptoms such as dysphagia (difficulty swallowing)
  • Changes in the appearance of the esophagus during endoscopy

How BP1.7881A Works

BP1.7881A works by blocking two types of histamine receptors: H1 and H4[1]. Histamine is a chemical involved in the body’s allergic and inflammatory responses. By blocking these receptors, BP1.7881A may help reduce inflammation and alleviate symptoms in both atopic dermatitis and eosinophilic esophagitis.

Potential Benefits

If proven effective, BP1.7881A could offer several benefits for patients:

  • Oral administration: The medication is taken by mouth, which may be more convenient than topical treatments for some patients[1][2].
  • Dual action: By targeting both H1 and H4 receptors, it may provide more comprehensive symptom relief than medications that target only one receptor type[1].
  • Potential for treating multiple conditions: If successful, BP1.7881A could be used to treat both skin and digestive allergic conditions[1][2].

Safety Considerations

As with any new medication, safety is a primary concern. The clinical trials are designed to carefully monitor for any side effects or adverse reactions. Some important safety considerations include:

  • Patients with certain heart conditions or abnormal ECG results are excluded from the studies[1][2].
  • The studies exclude patients with a history of certain medical conditions, including liver disease, HIV, and recent history of alcohol or drug abuse[1][2].
  • Pregnant or breastfeeding women are not eligible to participate in the studies[1][2].

It’s important to note that BP1.7881A is still in the investigational stage. More research is needed to fully understand its effectiveness and safety profile. Patients interested in this treatment should consult with their healthcare providers and consider participating in clinical trials if eligible.

Aspect Atopic Dermatitis Trial Eosinophilic Esophagitis Trial
Trial Phase Phase II Phase II
Study Design Randomized, double-blind, placebo-controlled Randomized, double-blind, placebo-controlled
Duration 12 weeks Up to 22 weeks
Primary Endpoint Change in EASI score Proportion of patients with ≤6 eos/hpf
Key Secondary Endpoints IGA score, EASI-75, EASI-90, Pruritus NRS Change in EDAQ score, EoE-EREFS, EoE-HSS
Dosage Form Film-coated tablet Orodispersible tablet
Maximum Daily Dose 270 mg 270 mg

FAQ

  • What is BP1.7881A and how does it work? BP1.7881A is a highly potent, selective, orally active dual histamine H1 and H4 receptors antagonist. It works by blocking specific histamine receptors, which may help reduce inflammation and symptoms associated with atopic dermatitis and eosinophilic esophagitis.
  • What conditions is BP1.7881A being tested for? BP1.7881A is currently being tested in clinical trials for two conditions: moderate-to-severe atopic dermatitis in adults and eosinophilic esophagitis in adults.
  • How is BP1.7881A administered? BP1.7881A is administered orally. In the trials, it is being tested as both a film-coated tablet and an orodispersible tablet.
  • What are the main goals of the clinical trials for BP1.7881A? The main goals of the clinical trials are to evaluate the efficacy and safety of BP1.7881A in treating atopic dermatitis and eosinophilic esophagitis. For atopic dermatitis, researchers are looking at improvements in skin symptoms, while for eosinophilic esophagitis, they are examining changes in eosinophil infiltration of the esophageal tissue.
  • How long do the clinical trials for BP1.7881A last? The clinical trial for atopic dermatitis lasts 12 weeks, while the trial for eosinophilic esophagitis has a treatment period of up to 22 weeks.

Ongoing Clinical Trials on Bp1.7881A

  • Study on BP1.7881 for Adults with Eosinophilic Esophagitis

    Recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    France Italy

  • Study on the Effectiveness and Safety of BP1.7881 for Adults with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    France Germany Poland

Glossary

  • Atopic dermatitis: A chronic inflammatory skin condition characterized by itchy, red, and swollen skin. It is a type of eczema that often begins in childhood but can affect people of all ages.
  • Eosinophilic esophagitis: A chronic immune system disease where a type of white blood cell (eosinophil) builds up in the lining of the esophagus, causing inflammation and difficulty swallowing.
  • Histamine receptors: Proteins on cell surfaces that bind to histamine, a chemical involved in immune responses. H1 and H4 receptors are specific types targeted by BP1.7881A.
  • EASI score: Eczema Area and Severity Index, a tool used to measure the extent and severity of atopic dermatitis.
  • Investigator's Global Assessment (IGA): A scale used by healthcare professionals to assess the overall severity of a skin condition, such as atopic dermatitis.
  • Pruritus: The medical term for itching, which is a common symptom in atopic dermatitis.
  • Eosinophil: A type of white blood cell that plays a role in allergic reactions and inflammation, particularly in eosinophilic esophagitis.
  • Esophagogastroduodenoscopy: A medical procedure that examines the lining of the esophagus, stomach, and upper part of the small intestine using a flexible tube with a camera.
  • EoE-EREFS: Eosinophilic Esophagitis-Endoscopic Reference Score, a system used to assess the severity of eosinophilic esophagitis during endoscopy.
  • Dysphagia: Difficulty or discomfort in swallowing, which is a common symptom in eosinophilic esophagitis.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bp1-7881-for-adults-with-moderate-to-severe-atopic-dermatitis/
  2. http://clinicaltrials.eu/trial/study-on-bp1-7881-for-adults-with-eosinophilic-esophagitis/